Reckitt, Abbott surge after winning an NEC case

Go back to Reckitt, Abbott surge after winning an NEC case

Abbott Labs (ABT) PT Raised to $149 at Barclays

November 4, 2024 4:52 AM EST

Barclays analyst Matt Miksic raised the price target on Abbott Labs (NYSE: ABT) to $149.00 (from $143.00) while maintaining a Overweight rating.

The analyst comments "Despite the Upward Move on Friday and 18% Rise Off July Lows, We See More than 25% Upside to Our Target for ABT:... More